MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
NLSP NLS Pharmaceutics
- 1.9500
- -0.4300-18.07%
Close Dec 20 16:00 ET
- 1.9000
- -0.0500-2.56%
Post 20:01 ET
4.62MMarket Cap-0.29P/E (TTM)
2.2851High1.7800Low262.54KVolume2.2300Open2.3800Pre Close531.69KTurnover17.51%Turnover RatioLossP/E (Static)2.37MShares24.336052wk High-0.50P/B2.92MFloat Cap1.730052wk Low--Dividend TTM1.50MShs Float294.0000Historical High--Div YieldTTM21.22%Amplitude1.7300Historical Low2.0250Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
NLS Pharmaceutics Stock Forum
$NLS Pharmaceutics (NLSP.US)$
Benzinga· 2 mins ago
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
Thursday, 19th December at 7:30 am
• This submission comes after successful INTERACT meeting with the FDA earlier this year.
• NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025
ZURICH, SWITZERLAND AND NESS ZIONA, ISRAEL / ACCESSWIRE / Decembe...
NLS Pharmaceutics CEO Issues Letter to Shareholders
Wednesday, 11th December at 7:30 am
ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ: NLSP)(NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, ...
NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market
NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market
Wednesday, 4th December at 1:15 pm
ZURICH, Dec. 4, 2024 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the...
No comment yet